ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for ...

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD)PALI-2108 demonstrates in ex vivo studies; ...

Thomas Bieber, University of Bonn, Germany, wasted no time in welcoming his colleagues from around the world to the ...

This orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development ... to provide API and manufacture drug product; our ability to enter into commercial ...

About PALI-2108 PALI-2108 is an orally administered, locally acting colon-specific PDE4 inhibitor prodrug in development for ... PALI-2108, and higher drug manufacturing costs, were offset by a ...

This orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients ... our ability to identify and qualify manufacturers to provide API and ...

The introduction of PDE5 inhibitors as safe and well-tolerated orally active drugs for the treatment of ... The application of PDE4 inhibitors appears to be a promising option to facilitate ...

The biotech is working on drugs with various mechanisms but the ... Readouts for ALTO-100 in bipolar depression and the transdermal PDE4 inhibitor ALTO-101 in cognitive impairment associated ...